Induction of mucosal and systemic immune response by oral immunization with H. pylori lysates encapsulated in poly(d,l-lactide-co-glycolide) microparticles

Kim, S.Y; Doh, H.J; Ahn, Jong-Kun; Ha, Y.J; Jang, Myoung Ho; Chung, Soo Il; Park, H.J

doi:10.1016/s0264-410x(98)00241-2

Cited by 48 publications

(19 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, many vaccines are based on particulate protein mixtures (such as inactivated viral particles39 or whole cell lysates40, 41) rather than single purified proteins. Antigen associated with large particles (500–1000 nm in diameter or greater) is known to be spontaneously cross-presented by dendritic cells following particle phagocytosis, via mechanisms that are still a matter of debate 32, 42–44.…”

Section: Resultsmentioning

confidence: 99%

Cytosolic Delivery Mediated via Electrostatic Surface Binding of Protein, Virus, or siRNA Cargos to pH-Responsive Core−Shell Gel Particles

Atukorale

et al. 2009

Biomacromolecules

View full text Add to dashboard Cite

We recently described a strategy for intracellular delivery of macromolecules, utilizing pHresponsive 'core-shell' structured gel particles. These crosslinked hydrogel particles disrupt endosomes with low toxicity by virtue of physical sequestration of an endosome-disrupting 'proton sponge' core inside a nontoxic hydrophilic shell. Here we tested the efficacy of this system for cytosolic delivery of a broad range of macromolecular cargos, and demonstrate the delivery of proteins, whole viral particles, or siRNA oligonucleotides into the cytosol of dendritic cells and epithelial cells via core-shell particles. We assessed the functional impact of particle delivery for vaccine applications, and found that cytosolic delivery of protein antigens in dendritic cells via the core-shell particles promotes priming of CD8 + T-cells at 100-fold lower doses than soluble protein.Functional gene knockdown following delivery of siRNA using the particles was demonstrated in epithelial cells. Based on these findings, these materials may be of interest for a broad range of biomedical applications.

show abstract

Section: Resultsmentioning

confidence: 99%

Cytosolic Delivery Mediated via Electrostatic Surface Binding of Protein, Virus, or siRNA Cargos to pH-Responsive Core−Shell Gel Particles

Atukorale

et al. 2009

Biomacromolecules

View full text Add to dashboard Cite

show abstract

“…Yet, even though intragastric administration received the highest dose, still it did not elicit any detectable immune response. It is likely that, despite the use of an antacid, the protein does not survive the harsh environment of the stomach and upper gastrointestinal tract and either needs to be protected (e.g, by encapsulation) [13] or accompanied by better adjuvants. We elected to use CpG ODN as adjuvant for this experiment because it has been reported safe for the different mucosas that we were testing.…”

Section: Discussionmentioning

confidence: 99%

Immunogenicity of Recombinant Helicobacter pylori Urease B Administered by Various Routes and with Different Adjuvants

Bégué

Moll²

2009

TOVACJ

View full text Add to dashboard Cite

Because of the high prevalence of Helicobacter pylori infection and the morbidity and mortality associated to the disease, development of a preventive vaccine has become a priority. To this goal, we produced recombinant H. pylori urease B (rUreB) and tested its immunogenicity in BALB/c mice when administered as 3 doses (week 0, 4 and 6) by either parenteral (intramuscular) or mucosal routes (intragastric, intranasal, intrarectal) and with the use of various adjuvants (none, CpG, alum or Freund's). The intramuscular route was more immunogenic than any mucosal route; of the mucosas, only intranasal induced modest levels of serum IgG. All adjuvants improved the seroresponse to plain rUreB and, of them, Freund's and alum were equally good and better than CpG ODN 1826. Stool IgA was barely detected by any immunization strategy.

show abstract

“…Oral immunization using muramyl dipeptide as adjuvant was tested in Helicobacter mustelae infected ferrets, but the results were disappointing [89]. Other potential adjuvants have also been tested with variable results in animals, but have not yet been tested in humans [90][91][92].…”

Section: Adjuvantsmentioning

confidence: 99%

Vaccines: An Ongoing Promise?

Alsahli

Farrell

Michetti

2001

Dig Dis

View full text Add to dashboard Cite

Over the past decade, intensive research has focused on developing a vaccine therapy for Helicobacter pylori. Substantial unresolved questions cloud the current approach, and the development of a vaccine against this unique organism has proved very challenging. Many candidate vaccines have been tested in animal models. The immunogenicity and the safety of some vaccine formulations have been recently evaluated through clinical trials, and the efficacy of these vaccine therapies in humans will be determined in the near future. This article will provide an overview of the current knowledge of natural and vaccine-induced immune responses to H. pylori infection. It will also review past vaccine successes and failures in animal models and the limited experience to date in using vaccine therapy in humans. Several obstacles to H. pylori vaccine development efforts along with the future direction of these efforts will be discussed.

show abstract

Induction of mucosal and systemic immune response by oral immunization with H. pylori lysates encapsulated in poly(d,l-lactide-co-glycolide) microparticles

Cited by 48 publications

References 31 publications

Cytosolic Delivery Mediated via Electrostatic Surface Binding of Protein, Virus, or siRNA Cargos to pH-Responsive Core−Shell Gel Particles

Cytosolic Delivery Mediated via Electrostatic Surface Binding of Protein, Virus, or siRNA Cargos to pH-Responsive Core−Shell Gel Particles

Immunogenicity of Recombinant Helicobacter pylori Urease B Administered by Various Routes and with Different Adjuvants

Vaccines: An Ongoing Promise?

Contact Info

Product

Resources

About